drugset
drugset / Trial / NCT03512860

Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study

NCT03512860 ↗

Phase 1 Completed 24 enrolled Estetra Quotient Sciences · collab
Non-randomizedCrossoverOpen-labelPrevention

Summary

The present study is designed to determine the effect of valproic acid (VAL), a UGT2B7 inhibiting drug, on the pharmacokinetics (PK) of estetrol (E4)

Timeline

Start
2018-04-12
Primary completion
2018-10-08
Completion
2018-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ESTETROL ANHYDROUS Other / unclassified — Oral
Subject Valproic Acid Small molecule — Oral
Subject drospirenone Unknown — Oral

Indications

No indication recorded.